Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2022/016565external-prioritypatent/WO2022177963A1/en
Application filed by Dr Falk Pharma Gmbh, Prometheus Biosciences IncfiledCriticalDr Falk Pharma Gmbh
Publication of DOP2023000160ApublicationCriticalpatent/DOP2023000160A/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
En el presente documento se describen anticuerpos anti-CD30L y composiciones farmacéuticas para el tratamiento de enfermedades y trastornos autoinmunitarios tales como la enteropatía inflamatoria (IBD), incluida la enfermedad de Crohn (CD) y la colitis ulcerosa (UC).Described herein are anti-CD30L antibodies and pharmaceutical compositions for the treatment of autoimmune diseases and disorders such as inflammatory enteropathy (IBD), including Crohn's disease (CD) and ulcerative colitis (UC).
DO2023000160A2022-02-162023-08-15
ANTI-CD30L ANTIBODIES AND USES OF THESE
DOP2023000160A
(en)
Compounds derived from cyclic pantheines; pharmaceutical composition comprising them; and its use to increase the concentrations of acetyl-coa, for the treatment of cancer, inflammatory disease, neurodegenerative disease, multiple sclerosis, among other diseases.